Premium
Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel‐resistant phenotype
Author(s) -
Solar Peter,
Feldman Laurie,
Jeong JeeYeong,
Busingye Jacqueline R.,
Sytkowski Arthur J.
Publication year - 2007
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.23071
Subject(s) - erythropoietin , paclitaxel , carboplatin , erythropoiesis , ovarian cancer , cancer research , apoptosis , erythropoietin receptor , biology , cisplatin , cancer cell , endocrinology , medicine , cancer , anemia , chemotherapy , biochemistry
Erythropoietin (Epo), a glycoprotein hormone that is the principal regulator of erythropoiesis, is known to act also on nonhematopoietic cell types. Epo receptors have been reported on several normal and neoplastic human cells and tissues, including ovarian cancer cells. We found that long‐term Epo treatment of A2780 cells resulted in the development of a phenotype exhibiting both enhanced Epo signaling, evidenced by increased peak levels of phospho‐Erk1/2 and increased paclitaxel resistance. This phenotypic effect was specific for paclitaxel, since no change in cisplatin or carboplatin sensitivity was observed. In addition, the change in phenotype was stable, even after the removal of Epo. Measurement of mono‐ and oligonucleosome formation revealed that long‐term Epo treated A2780 cells exhibited markedly less apoptosis than nonerythropoietin treated cells at essentially all concentrations of paclitaxel tested. Western blot analyses revealed that the long‐term Epo treated cells had significantly reduced expression of apoptosis‐related proteins Bcl‐2 and Bcl‐10. These findings may have implications for the clinical use of recombinant human Epo and other erythropoiesis stimulating agents to correct anemia in paclitaxel‐treated cancer patients. © 2007 Wiley‐Liss, Inc.